Context Therapeutics (NASDAQ:CNTX) Given New $5.00 Price Target at HC Wainwright

Context Therapeutics (NASDAQ:CNTX) had its target price raised by HC Wainwright from $4.00 to $5.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also issued reports on CNTX. Cantor Fitzgerald assumed coverage on shares of Context Therapeutics in a report on Thursday, October 2nd. They issued an “overweight” rating on the stock. Guggenheim began coverage on shares of Context Therapeutics in a research report on Thursday, September 18th. They issued a “buy” rating and a $5.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, October 8th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research note on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.40.

Context Therapeutics Stock Performance

Shares of CNTX traded up $0.05 during trading hours on Thursday, reaching $1.12. 198,791 shares of the company traded hands, compared to its average volume of 230,165. The stock’s fifty day moving average is $1.07 and its 200 day moving average is $0.85. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.10. The stock has a market cap of $100.46 million, a P/E ratio of -4.67 and a beta of 1.94.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). On average, equities research analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

A hedge fund recently raised its stake in Context Therapeutics stock. Clear Harbor Asset Management LLC grew its holdings in Context Therapeutics Inc. (NASDAQ:CNTX) by 60.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 92,804 shares of the company’s stock after buying an additional 35,000 shares during the quarter. Clear Harbor Asset Management LLC owned approximately 0.10% of Context Therapeutics worth $90,000 at the end of the most recent reporting period. 14.03% of the stock is owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.